Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01234649 · ClinicalTrials.gov registry record · Phase 3

Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)

A Phase 3 study, sponsored by Woman's.

Completed
Registry status
Phase 3
Development phase
153
Enrollment target

NCT01234649 is a Phase 3 study that has completed, run by Woman's. The registered enrollment target is 153 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01234649, a Phase 3 study, has completed, sponsored by Woman's.

COMPLETED
Registry status
Phase 3
Development phase
153 participants
Enrollment target

Study Summary

A diagnosis of gestational diabetes mellitus (GDM)has significant implications for the future health of the mother. GDM is often the culmination of years of unrecognized and unmodified diabetes risk factors that lead to overt and occult clinical manifestations during pregnancy. Systematic reviews of older studies conclude that 35-60% women with gestational diabetes will develop type 2 diabetes (DM2) at rates much greater than control groups who did not have glucose intolerance during pregnancy. Liraglutide may potentially delay disease progression in GDM considering the beta -(ß-)cell function improvement in DM2 and ß-cell mass shown to increase in animal models. This study will examine if the addition of liraglutide to metformin therapy is more effective than metformin alone in improving insulin sensitivity and normalizing insulin secretion in at-risk overweight/obese women with prior GDM.

Interventions

  • DRUG Metformin XR plus placebo
  • DRUG Metformin XR plus liraglutide

Trial Details

FieldValue
Enrollment Target 153 participants
Start Date 2011-08-11
Est. Completion 2019-06-14
Phase Phase 3

Sponsor

Woman's

17 total trials

What the Registry Record Tells You About NCT01234649

The ClinicalTrials.gov registry entry for NCT01234649 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 153 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Woman's, which has 17 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Metformin XR plus placebo is the first listed.

NCT01234649 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01234649 about?

NCT01234649 is a clinical study titled "Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM)". A diagnosis of gestational diabetes mellitus (GDM)has significant implications for the future health of the mother. GDM is often the culmination of years of unrecognized and unmodified diabetes risk factors that lead to overt and occult clinical manifestations during pregnancy. Systematic reviews of...

What is the current status of trial NCT01234649?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 153 participants. The study started on 2011-08-11. Estimated completion is 2019-06-14.

What interventions are being tested in trial NCT01234649?

The interventions under investigation include: Metformin XR plus placebo (DRUG), Metformin XR plus liraglutide (DRUG).

Who is sponsoring clinical trial NCT01234649?

This trial is sponsored by Woman's, which has 17 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.